Nav: Home

Next-generation metabolomics may facilitate the discovery of new antidepressants

August 06, 2018

Depression is one of the most common diseases that affects at least 4.4% of the world population since 2015. Current antidepressants are limited by their undesirable side effects and slow onset. The development of drugs for depression is particularly challenging due to the complexity of the symptoms, heterogeneity and comorbid diagnosis. Indeed, only one new drug was approved for the treatment of depression by the US FDA in the last 10 years (2008-2018). More efforts are urgently needed to enhance the productivity and creativity of the discovery and development (R&D) of new antidepressants

The origins of metabolomics can be traced back to the newborn screening of inborn errors of metabolism in clinical chemistry since the 1960s, which was much earlier than genomics and proteomics. With the advancements of separation and mass spectrometry detection techniques, metabolomics is entering into a new era in which researchers can gain more insights about metabolic pathways and their significance in health and disease.

Dr. Kefeng Li from the University of California, San Diego, (UCSD, San Diego, CA, USA) has been working in the field of metabolomics for years. In this paper, he and the colleagues summarized the analytical platforms for NGM and its main applications in antidepressants R&D. These platforms provide broad coverage of different classes of metabolites, superior detection sensitivity, high resolution and mass accuracy. Because of these advantages, NGM has demonstrated great potential in all the stages of pharmaceutical R&D.

Dr. Li, the corresponding author of the paper comments, "We specifically selected albiflorin, a botanical medicine isolated from Peony to demonstrate the practical utility of NGM". Natural products tend to have multiple targets and unpredictable toxicity. NGM analysis showed the potential antidepressant targets of albiflorin. NGM also confirmed the low toxicity of albiflorin. It might need over 5 years of work using traditional approaches to come up with the same conclusion that only needs 1-2 years for NGM. NMG really speeds up the development of albiflorin as a new class of antidepressant. Dr. Li adds, "Albiflorin is a very promising multi-target drug candidate with a low toxic profile, which overcomes the side effects of some of the current commonly used antidepressants".

In regarding to the future of NGM, Dr. Li underlines that "The bottlenecks of metabolomics have still not been completely solved. Standardization of metabolomic procedures and understanding the biology behind metabolomic big data are required to be further studied."
-end-
For more information, please visit: http://www.eurekaselect.com/164079

Bentham Science Publishers

Related Depression Articles:

Children with social anxiety, maternal history of depression more likely to develop depression
Although researchers have known for decades that depression runs in families, new research from Binghamton University, State University of New York, suggests that children suffering from social anxiety may be at particular risk for depression in the future.
Depression and use of marijuana among US adults
This study examined the association of depression with cannabis use among US adults and the trends for this association from 2005 to 2016.
Maternal depression increases odds of depression in offspring, study shows
Depression in mothers during and after pregnancy increased the odds of depression in offspring during adolescence and adulthood by 70%.
Targeting depression: Researchers ID symptom-specific targets for treatment of depression
For the first time, physician-scientists at Beth Israel Deaconess Medical Center have identified two clusters of depressive symptoms that responded to two distinct neuroanatomical treatment targets in patients who underwent transcranial magnetic brain stimulation (TMS) for treatment of depression.
A biological mechanism for depression
Researchers report that in depressed individuals there are increased amounts of an unmodified structural protein, called tubulin, in lipid rafts compared with non-depressed individuals.
Depression in adults who are overweight or obese
In an analysis of primary care records of 519,513 UK adults who were overweight or obese between 2000-2016 and followed up until 2019, the incidence of new cases of depression was 92 per 10,000 people per year.
Why stress doesn't always cause depression
Rats susceptible to anhedonia, a core symptom of depression, possess more serotonin neurons after being exposed to chronic stress, but the effect can be reversed through amygdala activation, according to new research in JNeurosci.
Which comes first: Smartphone dependency or depression?
New research suggests a person's reliance on his or her smartphone predicts greater loneliness and depressive symptoms, as opposed to the other way around.
Depression breakthrough
Major depressive disorder -- referred to colloquially as the 'black dog' -- has been identified as a genetic cause for 20 distinct diseases, providing vital information to help detect and manage high rates of physical illnesses in people diagnosed with depression.
CPAP provides relief from depression
Researchers have found that continuous positive airway pressure (CPAP) treatment of obstructive sleep apnea (OSA) can improve depression symptoms in patients suffering from cardiovascular diseases.
More Depression News and Depression Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: The Power Of Spaces
How do spaces shape the human experience? In what ways do our rooms, homes, and buildings give us meaning and purpose? This hour, TED speakers explore the power of the spaces we make and inhabit. Guests include architect Michael Murphy, musician David Byrne, artist Es Devlin, and architect Siamak Hariri.
Now Playing: Science for the People

#576 Science Communication in Creative Places
When you think of science communication, you might think of TED talks or museum talks or video talks, or... people giving lectures. It's a lot of people talking. But there's more to sci comm than that. This week host Bethany Brookshire talks to three people who have looked at science communication in places you might not expect it. We'll speak with Mauna Dasari, a graduate student at Notre Dame, about making mammals into a March Madness match. We'll talk with Sarah Garner, director of the Pathologists Assistant Program at Tulane University School of Medicine, who takes pathology instruction out of...
Now Playing: Radiolab

What If?
There's plenty of speculation about what Donald Trump might do in the wake of the election. Would he dispute the results if he loses? Would he simply refuse to leave office, or even try to use the military to maintain control? Last summer, Rosa Brooks got together a team of experts and political operatives from both sides of the aisle to ask a slightly different question. Rather than arguing about whether he'd do those things, they dug into what exactly would happen if he did. Part war game part choose your own adventure, Rosa's Transition Integrity Project doesn't give us any predictions, and it isn't a referendum on Trump. Instead, it's a deeply illuminating stress test on our laws, our institutions, and on the commitment to democracy written into the constitution. This episode was reported by Bethel Habte, with help from Tracie Hunte, and produced by Bethel Habte. Jeremy Bloom provided original music. Support Radiolab by becoming a member today at Radiolab.org/donate.     You can read The Transition Integrity Project's report here.